--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-275461" form_type: "8-K" ticker: "RNAC" cik: "0001453687" company_name: "Cartesian Therapeutics, Inc." filed_at: "2023-11-13T23:59:59+00:00" generated_at: "2026-06-08T04:53:23.509240+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # Selecta completes merger with Cartesian; renamed Cartesian Therapeutics, ticker RNAC ## Summary - Merger closed Nov 13; Selecta issued 6.7M common shares and 384,931 Series A Preferred to Cartesian holders. - Insider PIPE of $60.25M from board member Springer and former CEO Kalayoglu trust; 149,330 Series A Preferred sold. - New officers appointed: Metin Kurtoglu (COO), Milos Miljkovic (CMO), Chris Jewell (CSO); former CMO/CSO/COO resigned. - CVRs to be issued to Selecta stockholders, entitling them to 100% of future Sobi license milestones/royalties. - Series A Preferred convertible into 1,000 common shares each, subject to stockholder approval of charter amendment. ## SEC filing metadata - accession: 0001193125-23-275461 - form_type: 8-K - ticker: RNAC - cik: 0001453687 - company_name: Cartesian Therapeutics, Inc. - filed_at: 2023-11-13T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/d869185d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-275461 - JSON: https://secwatch.observer/filing/0001193125-23-275461.json - Plain text: https://secwatch.observer/filing/0001193125-23-275461.txt ## Key facts - Executive change Lloyd Johnston resigned as Chief Operations Officer at Cartesian Therapeutics, Inc.. - Action: resigned - Role: Chief Operations Officer source text: each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - Executive change Chris Jewell was appointed as Chief Scientific Officer at Cartesian Therapeutics, Inc.. - Action: appointed - Role: Chief Scientific Officer source text: the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - Executive change Peter Traber resigned as Chief Medical Officer at Cartesian Therapeutics, Inc.. - Action: resigned - Role: Chief Medical Officer source text: each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - Executive change Kei Kishimoto resigned as Chief Scientific Officer at Cartesian Therapeutics, Inc.. - Action: resigned - Role: Chief Scientific Officer source text: each of Peter Traber, Kei Kishimoto and Lloyd Johnston resigned as Chief Medical Officer, Chief Scientific Officer and Chief Operations Officer, respectively evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - Executive change Milos Miljkovic was appointed as Chief Medical Officer at Cartesian Therapeutics, Inc.. - Action: appointed - Role: Chief Medical Officer source text: the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - Executive change Metin Kurtoglu was appointed as Chief Operating Officer at Cartesian Therapeutics, Inc.. - Action: appointed - Role: Chief Operating Officer source text: the Board appointed Metin Kurtoglu as the Company’s Chief Operating Officer, Milos Miljkovic as the Company’s Chief Medical Officer, and Chris Jewell as the Company’s Chief Scientific Officer. evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - Governance Changes Cartesian Therapeutics, Inc.: Company amended its restated certificate of incorporation to change corporate name to Cartesian Therapeutics, Inc (effective 2023-11-13). - Change: charter amendment - Effective: 2023-11-13 source text: On November 13, 2023, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to the Charter to change its corporate name to Cartesian Therapeutics, Inc. evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - M&A Transactions Cartesian Therapeutics, Inc. completed an acquisition involving Cartesian Therapeutics, Inc. for 6,723,662 shares of the common stock of Selecta and 384,930.725 shares of Series A Preferred Stock (closed 2023-11-13). - Action: acquisition - Counterparty: Cartesian Therapeutics, Inc. - Consideration: 6,723,662 shares of the common stock of Selecta and 384,930.725 shares of Series A Preferred Stock - Closing: 2023-11-13 source text: Agreement and Plan of Merger On November 13, 2023, Selecta Biosciences, Inc., a Delaware corporation (“Selecta” or the “Company”), acquired Cartesian Therapeutics, Inc., a Delaware corporation (“Cartesian”), in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the “Merger Agreement”), by and among Selecta, Sakura Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Selecta (“First Merger Sub”), Sakura Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Selecta (“Second Merger Sub”), and Cartesian. evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm - Material Agreements Cartesian Therapeutics, Inc. entered into Merger Agreement with Selecta Biosciences, Inc.. - Action: entry - Agreement: merger - Counterparty: Selecta Biosciences, Inc. source text: Pursuant to the Merger Agreement, Selecta has agreed to hold a stockholders’ meeting to submit the following matters to its stockholders for their consideration evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000119312523275461/0001193125-23-275461-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.